Utilizing Pemetrexed plus Platinum as First-line Treatment in East-Asian Elderly Patients with Advan

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户：A88851258

【摘要】

：

【作者】

：

Shun ku Yi-long Wu Ying Cheng Cai-cun Zhou Jie Wang James Chih-Hsin Yang Ping-hai Zhang Xiao-qing Zhang Xin Wang Mauro Orlando

【机构】

：

200030 Lung Cancer Center, Shanghai Chest Hospital, affiliated to Shanghai Jiao Tong University, Sha

【出处】

：

第十七届全国临床肿瘤学大会暨2014年CSCO学术年会

【发表日期】

：

2014年11期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective: A meta-analysis was recently conducted in East-Asian advanced non-squamous non-small cell lung cancer (nsq-NSCLC) patients based on available individual patient data from three randomized phase Ⅲ trials (JMDB, S380 and JMIL).Particularly, it is our interest here to look at the efficacy and safety of pemetrexed plus platinum and other platinum based doublet regimens in elderly East-Asian patients.

其他文献

Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C

Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun

会议

Tumorigenic potential of circulating tumor cells in pulmonary venous blood from Non-Small Cell Lung

Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)

Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells

会议

Prophylactic cranial irradiation improved the overall survival of patients with surgically resected

Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of co

会议

Pemetrexed continuation maintenance: An effective tolerable strategy for treating nonsquamous non-sm

Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrol

会议

Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in NSCLC that drive

Objeetive: NSCLC are particularly aggressive tumors, with high invasive properties and metastatic potential.About 40％ stage Ⅰ and 60％ stage Ⅱ NSCLC patients are dying of distant metastases within 5 ye

会议

The Feasibility of EML4-ALK fusion gene, EGFR and K-ras mutations Detections by Malignant Pleural ef

Objective:To identify the feasibility of pleural effusion detection of epidermal growth factor receptor (EGFR) mutations, echinoderm microtubule-associated protein like 4 (EML4)-anaplastic lymphoma ki

会议

Nivolumab联合厄洛替尼治疗表皮生长因子受体突变(EGFR MT)的晚期NSCLC患者的安全性和缓解率

背景:厄洛替尼已获FDA批准用于表皮生长因子受体突变(EGFR MT)的非小细胞肺癌(NSCLC)一线治疗,中位无进展生存期(PFS)为10.4个月.Nivolumab是全人源化IgG4程序性死亡1(PD-1)免疫检查点抑制剂抗体,作为单药治疗晚期NSCLC患者显示了出令人鼓舞的安全性与生存获益.临床前数据支持EGFR路径活化PD-L1表达与免疫逃避在EGFR驱动的肺肿瘤中的作用.本摘要将报告评估

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) as initial therapy in patients with

Objective:Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells.Pembro is a potent and highly selective humanized monoclonal antibody against PD-1 design

会议

Functional Polymorphisms in Cancer Stem Cell Marker Gene CD133 Predict Local Recurrence and Distant

Objective: Cancer stem cells (CSCs) are believed to cause local recurrence, distant metastasis, radiotherapy and chemotherapy resistance.We hypothesized that genetic variation in CD133 (the official n

会议

Utilizing Pemetrexed plus Platinum as First-line Treatment in East-Asian Elderly Patients with Advan

与本文相关的学术论文